NanoEcho strengthens its position through an agreement with Clinical Trial Consultants for the upcoming clinical phase

NanoEcho announces today that the company has entered an agreement with Clinical Trial Consultants (CTC), who will contribute with expertise, guidance, and preparatory activities for the upcoming clinical registration study.

CTC is a Clinical Research Organization (CRO) and thereby specialised in planning, executing, and reporting clinical studies. The agreement means that CTC will provide expertise and guidance during the initial phase of planning and preparations for NanoEcho’s upcoming clinical registration study. This agreement constitutes a significant part of the clinical preparations.

“The signed agreement marks a substantial milestone in the preparations for the upcoming clinical registration study. Through this agreement with CTC, we will benefit from their specialised expertise and position ourselves well for our clinical phase”, says Linda Persson, CEO of NanoEcho.

Pågående emission
i NanoEcho

Erbjudande om att teckna aktier i NanoEcho AB (publ) i samband med IPO
Teckningstid: 29 maj – 28 juni

We use cookies to enhance your experience on our website and analyze our traffic. By clicking ‘Accept,’ you consent to our use of cookies. You can learn more about the types of cookies we use and how to manage them in our privacy policy.